Hope for rare bone and skin condition: new drug trial launches

NCT ID NCT06011889

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether etanercept, a drug that blocks inflammation, can reduce pain and disease activity in adults with SAPHO syndrome—a rare condition affecting bones, joints, and skin. Participants must have tried standard treatments like NSAIDs without enough relief. The trial compares etanercept to a placebo over 12 weeks to see if it improves symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SAPHO SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

SAPHO syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centrum Wsparcia Badań Klinicznych

    RECRUITING

    Warsaw, Masovian Voivodeship, 02-637, Poland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••